ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment

BACKGROUND: Measurement of the success of antitrypanosomal treatment for Chagas disease is difficult, particularly in the chronic phase of the disease, because anti-Trypanosoma cruzi antibodies persist in serum for prolonged periods. We studied the effects of nifurtimox administered by two different...

Descripción completa

Detalles Bibliográficos
Autores principales: Rivero, Rocio, Esteva, Mónica Inés, Huang, Erya, Colmegna, Leylen, Altcheh, Jaime, Grossmann, Ulrike, Ruiz, Andrés Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325040/
https://www.ncbi.nlm.nih.gov/pubmed/37352322
http://dx.doi.org/10.1371/journal.pntd.0011440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325040/
https://www.ncbi.nlm.nih.gov/pubmed/37352322
http://dx.doi.org/10.1371/journal.pntd.0011440

Ejemplares similares